THE WAY FOR OPTIMIZATION OF DISTANT RADIATION THERAPY IN PROSTATE CANCER

• Main Author: A. S. Balkanov
• Format: Article
• Language: Russian
• Published: MONIKI 2016-02-01
• Series: Alʹmanah Kliničeskoj Mediciny
• Subjects: prostate cancer; radiation therapy; 5-year survival; costs of radiation therapy; prostate-specific antigen; elderly; comorbidity
• Online Access: https://www.almclinmed.ru/jour/article/view/77
• ISSN: 2072-0505; 2587-9294

Background: The rationale for distant gamma therapy (DGT) in prostate cancer patients is the data of its effectiveness in combination with modern planner devices, as well as lower costs, compared to the use of a linear accelerator.Aim: To access the impact of DGT based on a 3D planning software “Amphora” on the 5-year survival rate depending on the main predictors of treatment efficacy in prostate cancer patients.Materials and methods: The study included 34 prostate cancer patients who received low-dose DGT (total focal dose of 62 to 70 Gr). Androgen deprivation was used in 73.5% of patients for 6 to 12 months.Results: The patients with a baseline pros tate-specific antigen level < 20 ng/ml had the highest 5-year survival rate of 86%. There was no significant difference in a 5-year survival that depending on a total focal dose (< 64 Gr; ≥ 64 Gr) of DGT if used in combination with androgen deprivation. Conclusion: This data represents only the first step in establishment of the criteria to choose the type of DGT in prostate cancer patients. The optimization of a treatment strategy based on a thorough analysis of data, including that on comorbidities and their severity, would make the use of DGT more rational that will reduce costs of treatment.